A Study Evaluating Nexagon™ in the Treatment of Skin Wounds.
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
Nexagon™ is a novel compound that promotes wound healing by temporarily disrupting cellular
communication at the wound site, thereby promoting accelerated healing, reducing inflammation
and pain. This randomized double-blind study will assess the safety, tolerability and
clinical effect of Nexagon™ when applied to skin wounds created by punch biopsy in healthy
volunteers. 43 healthy, fair-skinned males and females between ages 18-40 will be enrolled.
Subjects will be reviewed again at 3 months and 9 months for follow-up safety assessments and
wound appearance evaluation.
Phase:
Phase 1
Details
Lead Sponsor:
CoDa Therapeutics Inc. OcuNexus Therapeutics, Inc.